Haematologica
HAEMATOL/2015/136275
Version 5

# A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients

Hendrika Hazendonk, Karin Fijnvandraat, Janske Lock, Marriëtte Driessens, Felix Van Der Meer, Karina Meijer, Marieke Kruip, Britta Laros-van Gorkom, Marjolein Peters, Saskia de Wildt, Frank Leebeek, Marjon Cnossen, and Ron Mathôt

Disclosures: All authors have completed the Competing Interest form and have no financial or personal relationships that could inappropriately influence the study. With regards to other projects and travel grants: KM has received unrestricted research support from Bayer and Baxter. MP has received unrestricted research grants from Bayer, Pfizer, CSL Behring, Baxter and Novo Nordisk. BL has received unrestricted educational grants from Baxter and CSL Behring. MK has received an unrestricted grant from Pfizer. FL has received unrestricted research grants from CSL Behring and Baxter and has served on advisory boards of CSL Behring and Baxter. KF has received unrestricted educational grants from CSL Behring and Bayer and is member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter. MC has received unrestricted research/educational funding for various projects and other “OPTI-CLOT” projects as well as travel funding from the following companies: Pfizer, Baxter, Bayer Schering Pharma, Novo Nordisk Novartis and CSL Behring. The remaining authors declare no competing financial interests.

Contributions: MC and RM were responsible for protocol development. HH was responsible for the implementation of the study protocol, data collection and analysis. JL was responsible for data collection in the primary phase. KM, MP, BL and FM monitored patient inclusion. MC and RM supervised the study, with FL and KF giving critical guidance during the project. HH, MC and RM are the main authors of the paper. All authors substantially contributed to the writing and critically revised the manuscript, with approval of the final draft.